Siemens' RAPIDPoint 500e Blood Gas Analyzer Receives US FDA Clearance to Aid in COVID-19 Care

Siemens Healthineers’ (Erlangen, Germany) latest critical care testing solution, the RAPIDPoint 500e Blood Gas Analyzer, has received clearance from the US Food and Drug Administration, and is now available in the US, Europe and countries requiring the CE mark. The RAPIDPoint 500e Blood Gas Analyzer belongs to Siemens’ blood gas portfolio which is supporting COVID-19 response efforts, where blood gas testing plays a critical role in managing infected patients.

The RAPIDPoint 500e Blood Gas Analyzer generates blood gas, electrolyte, metabolite, CO-oximetry, and neonatal bilirubin results, which are used to diagnose and monitor critically ill patients in the intensive care unit, operating room, or emergency room. Blood gas testing is often required for ventilator-assisted patients and those undergoing evaluation for respiratory distress, providing insights into a patient’s oxygenation level. Additionally, the RAPIDPoint 500e Blood Gas Analyzer uses Integri-sense Technology, a comprehensive series of automated functional checks that are designed to deliver accurate test results at the point-of-care.


“Point-of-care teams monitoring respiratory conditions in critical care settings need a blood gas testing solution that delivers fast, accurate results and increases workflow efficiencies. A safe operating environment amid growing concerns about cybersecurity threats in healthcare is also important,” said Christoph Pedain, Head of Point of Care Diagnostics, Siemens Healthineers. “The RAPIDPoint 500e Blood Gas Analyzer has become a trusted instrument in Europe’s endeavor to combat COVID-19 and to help address an unprecedented demand for blood gas testing in affected respiratory patients.”

Related Links:
Siemens Healthineers